Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Clinical Trial of PXL770 for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Next Previous
Trial Profile

A Phase 2b Clinical Trial of PXL770 for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PXL 770 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors Poxel

Most Recent Events

  • 21 Jul 2021 According to a Poxel media release, initiation of this study will be postponed, pending results from the ongoing PXL065 Phase 2 trials in NASH and both Phase 2a biomarker studies in AMN.
  • 12 Jul 2021 According to a Poxel media release, initiation of the NASH Phase 2b trial for PXL770, a first-in-class, oral direct AMPK activator, will be postponed.
  • 14 Dec 2020 According to a Poxel media release, the trial is expected to begin during the second half of 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top